Unaudited financial results for the quarter and half year ended 30.09.2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Decipher Labs Limited (formerly Combat Drugs Limited) reported its unaudited results for Q2 and H1 FY26 (ended Sept 30, 2025). On a standalone basis, H1 FY26 revenue rose sharply to Rs 93.45 lakhs from Rs 36.72 lakhs in H1 FY25, while the loss narrowed to Rs 5.96 lakhs from Rs 18.70 lakhs. However, on a consolidated basis, revenue fell about 46% to Rs 723.74 lakhs from Rs 1,330.77 lakhs, and the company swung to a loss of Rs 340.66 lakhs compared to a small profit in H1 FY25. Net cash used in operating activities was Rs 0.67 lakhs standalone and Rs 218.87 lakhs consolidated. The board also appointed Mr. Dalavath Amar Singh as an Additional Executive Director for two years at Rs 6 lakhs per annum. Auditor Ramanatham & Rao issued an unqualified review report.
Mixed picture for shareholders — standalone numbers show improving revenue and shrinking losses, but the consolidated business (driven by subsidiaries in the USA and Bahrain) deteriorated sharply with revenue halving and a large loss. Combined with negative operating cash flows on both bases, this is a cautious signal for the stock and highlights continued volatility.